DCPH - Here's Why Deciphera Pharmaceuticals Rose 31.6% in December
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) lept over 31% last month, according to data from S&P Global Market Intelligence. The monthly run-up topped 45% at one point before shares cooled off in the final days of the decade. Despite that, the stock erupted for a 196% gain in 2019.
There wasn't any company-specific news to send the pharma stock soaring, but investors have kept Deciphera Pharmaceuticals near the top of the list for potential buyout candidates. As such, when merger and acquisition activity picks up in the industry, shares are likely to become a little volatile. The speculation isn't entirely unwarranted.
Image source: Getty Images.